Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.97
ICCC's Cash to Debt is ranked lower than
64% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ICCC: 4.97 )
Ranked among companies with meaningful Cash to Debt only.
ICCC' s 10-Year Cash to Debt Range
Min: 1  Med: 4.72 Max: No Debt
Current: 4.97
Equity to Asset 0.87
ICCC's Equity to Asset is ranked higher than
75% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ICCC: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
ICCC' s 10-Year Equity to Asset Range
Min: 0.57  Med: 0.85 Max: 0.97
Current: 0.87
0.57
0.97
F-Score: 8
Z-Score: 11.87
M-Score: -2.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.98
ICCC's Operating margin (%) is ranked higher than
77% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ICCC: 6.98 )
Ranked among companies with meaningful Operating margin (%) only.
ICCC' s 10-Year Operating margin (%) Range
Min: -25.21  Med: 3.91 Max: 18.82
Current: 6.98
-25.21
18.82
Net-margin (%) 3.77
ICCC's Net-margin (%) is ranked higher than
72% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ICCC: 3.77 )
Ranked among companies with meaningful Net-margin (%) only.
ICCC' s 10-Year Net-margin (%) Range
Min: -10.12  Med: 3.90 Max: 39.43
Current: 3.77
-10.12
39.43
ROE (%) 3.49
ICCC's ROE (%) is ranked higher than
77% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. ICCC: 3.49 )
Ranked among companies with meaningful ROE (%) only.
ICCC' s 10-Year ROE (%) Range
Min: -5.26  Med: 1.91 Max: 53.2
Current: 3.49
-5.26
53.2
ROA (%) 2.96
ICCC's ROA (%) is ranked higher than
79% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. ICCC: 2.96 )
Ranked among companies with meaningful ROA (%) only.
ICCC' s 10-Year ROA (%) Range
Min: -4.57  Med: 1.63 Max: 43.15
Current: 2.96
-4.57
43.15
ROC (Joel Greenblatt) (%) 13.68
ICCC's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. ICCC: 13.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICCC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27.93  Med: 5.56 Max: 53.7
Current: 13.68
-27.93
53.7
Revenue Growth (3Y)(%) 13.60
ICCC's Revenue Growth (3Y)(%) is ranked higher than
71% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ICCC: 13.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICCC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -19.3  Med: 4.40 Max: 17
Current: 13.6
-19.3
17
EPS Growth (3Y)(%) -24.60
ICCC's EPS Growth (3Y)(%) is ranked lower than
72% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ICCC: -24.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICCC' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.5  Med: -4.40 Max: 99.2
Current: -24.6
-42.5
99.2
» ICCC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ICCC Guru Trades in Q2 2014

Jim Simons 15,500 sh (+13.14%)
» More
Q3 2014

ICCC Guru Trades in Q3 2014

Jim Simons 17,800 sh (+14.84%)
» More
Q4 2014

ICCC Guru Trades in Q4 2014

Jim Simons 19,200 sh (+7.87%)
» More
Q1 2015

ICCC Guru Trades in Q1 2015

Jim Simons 21,600 sh (+12.50%)
» More
» Details

Insider Trades

Latest Guru Trades with ICCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 123.67
ICCC's P/E(ttm) is ranked lower than
75% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ICCC: 123.67 )
Ranked among companies with meaningful P/E(ttm) only.
ICCC' s 10-Year P/E(ttm) Range
Min: 14.74  Med: 33.89 Max: 669
Current: 123.67
14.74
669
PE(NRI) 94.40
ICCC's PE(NRI) is ranked lower than
78% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. ICCC: 94.40 )
Ranked among companies with meaningful PE(NRI) only.
ICCC' s 10-Year PE(NRI) Range
Min: 14.8  Med: 35.00 Max: 334.5
Current: 94.4
14.8
334.5
P/B 3.58
ICCC's P/B is ranked higher than
73% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ICCC: 3.58 )
Ranked among companies with meaningful P/B only.
ICCC' s 10-Year P/B Range
Min: 0.41  Med: 1.47 Max: 3.59
Current: 3.58
0.41
3.59
P/S 3.90
ICCC's P/S is ranked higher than
83% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. ICCC: 3.90 )
Ranked among companies with meaningful P/S only.
ICCC' s 10-Year P/S Range
Min: 0.87  Med: 2.45 Max: 6.06
Current: 3.9
0.87
6.06
POCF 25.52
ICCC's POCF is ranked higher than
75% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. ICCC: 25.52 )
Ranked among companies with meaningful POCF only.
ICCC' s 10-Year POCF Range
Min: 7.73  Med: 18.89 Max: 107
Current: 25.52
7.73
107
EV-to-EBIT 51.94
ICCC's EV-to-EBIT is ranked lower than
55% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. ICCC: 51.94 )
Ranked among companies with meaningful EV-to-EBIT only.
ICCC' s 10-Year EV-to-EBIT Range
Min: -506.9  Med: 6.10 Max: 163.6
Current: 51.94
-506.9
163.6
Current Ratio 8.10
ICCC's Current Ratio is ranked higher than
67% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. ICCC: 8.10 )
Ranked among companies with meaningful Current Ratio only.
ICCC' s 10-Year Current Ratio Range
Min: 2.71  Med: 8.10 Max: 30.82
Current: 8.1
2.71
30.82
Quick Ratio 7.28
ICCC's Quick Ratio is ranked higher than
65% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ICCC: 7.28 )
Ranked among companies with meaningful Quick Ratio only.
ICCC' s 10-Year Quick Ratio Range
Min: 1.71  Med: 6.96 Max: 26.79
Current: 7.28
1.71
26.79
Days Inventory 93.80
ICCC's Days Inventory is ranked higher than
60% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. ICCC: 93.80 )
Ranked among companies with meaningful Days Inventory only.
ICCC' s 10-Year Days Inventory Range
Min: 58.81  Med: 124.82 Max: 259.57
Current: 93.8
58.81
259.57
Days Sales Outstanding 31.31
ICCC's Days Sales Outstanding is ranked higher than
78% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ICCC: 31.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICCC' s 10-Year Days Sales Outstanding Range
Min: 16.22  Med: 38.30 Max: 56.67
Current: 31.31
16.22
56.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.22
ICCC's Price/Net Cash is ranked lower than
55% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. ICCC: 12.22 )
Ranked among companies with meaningful Price/Net Cash only.
ICCC' s 10-Year Price/Net Cash Range
Min: 1.05  Med: 3.98 Max: 61.73
Current: 12.22
1.05
61.73
Price/Net Current Asset Value 7.86
ICCC's Price/Net Current Asset Value is ranked higher than
60% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. ICCC: 7.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICCC' s 10-Year Price/Net Current Asset Value Range
Min: 0.77  Med: 2.71 Max: 12.02
Current: 7.86
0.77
12.02
Price/Tangible Book 3.42
ICCC's Price/Tangible Book is ranked higher than
78% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ICCC: 3.42 )
Ranked among companies with meaningful Price/Tangible Book only.
ICCC' s 10-Year Price/Tangible Book Range
Min: 0.5  Med: 1.65 Max: 5.5
Current: 3.42
0.5
5.5
Price/Projected FCF 9.65
ICCC's Price/Projected FCF is ranked lower than
62% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ICCC: 9.65 )
Ranked among companies with meaningful Price/Projected FCF only.
ICCC' s 10-Year Price/Projected FCF Range
Min: 0.49  Med: 1.58 Max: 85.17
Current: 9.65
0.49
85.17
Price/Median PS Value 1.60
ICCC's Price/Median PS Value is ranked lower than
51% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ICCC: 1.60 )
Ranked among companies with meaningful Price/Median PS Value only.
ICCC' s 10-Year Price/Median PS Value Range
Min: 0.29  Med: 0.83 Max: 2.28
Current: 1.6
0.29
2.28
Price/Peter Lynch Fair Value 1.00
ICCC's Price/Peter Lynch Fair Value is ranked lower than
2173% of the 49 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ICCC: 1.00 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ICCC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.16  Med: 0.51 Max: 3.8
Current: 1
0.16
3.8
Price/Graham Number 3.94
ICCC's Price/Graham Number is ranked higher than
57% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. ICCC: 3.94 )
Ranked among companies with meaningful Price/Graham Number only.
ICCC' s 10-Year Price/Graham Number Range
Min: 0.25  Med: 1.30 Max: 6.03
Current: 3.94
0.25
6.03
Earnings Yield (Greenblatt) (%) 1.91
ICCC's Earnings Yield (Greenblatt) (%) is ranked higher than
85% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ICCC: 1.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICCC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.6  Med: 5.80 Max: 881.5
Current: 1.91
0.6
881.5
Forward Rate of Return (Yacktman) (%) 42.96
ICCC's Forward Rate of Return (Yacktman) (%) is ranked higher than
91% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. ICCC: 42.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ICCC' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -7.8  Med: -0.90 Max: 8.5
Current: 42.96
-7.8
8.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:IUL.Germany,
ImmuCell Corporation was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987. It completed an initial public offering of common stock in 1987. The Company is engaged in the development, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industry. Its purpose is to create scientifically proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. At the same time, it is investigating ways to develop new products utilizing First Defense and Nisin technologies. Its product, First Defense, is manufactured from cows' colostrum using its proprietary vaccine and whey protein purification technologies. The target disease, bovine enteritis (calf scours), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. First DefenseÒ is the only USDA-licensed, orally delivered scours preventive product on the market for calves with claims against E. coli K99 and coronavirus. During the fourth quarter of 2011, it sold the 11,000,000th dose of First DefenseÒ, since receiving USDA approval of this product in 1991. In 1999, it acquired Wipe OutÒ Dairy Wipes, which is its second source of product sales revenue. That transaction included the purchase of certain equipment, trademarks and a license of intellectual property, including several issued patents, covering the product and rights to develop skin and environmental sanitizing applications of the Nisin technology. Wipe OutÒ Dairy Wipes consist of biodegradable towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking. Nisin is an antibacterial peptide that has been demonstrated in clinical studies to be an effective aid in the reduction of mastitis-causing organisms in dairy cows. First DefenseÒ is generally sold through large, financially strong distributors, which it believes has resulted in minimal bad debt with respect to this product. The Company provides for a 50% account credit for domestic distributors on expired First DefenseÒ product, which has a two-year shelf life resulting in an immaterial amount of returns. The Company's competition in the animal health market includes other biotechnology companies and major animal health companies. In addition to direct competition from oral antibody products, First DefenseÒ also competes for market share against vaccine products that are used to increase the production of antibodies by the dam that can then be transferred through the mother's milk to the calf and against vaccine products that are administered to the newborn calf.
» More Articles for ICCC

Headlines

Articles On GuruFocus.com
ImmuCell Reports Results From Rotavirus Pivotal Effectiveness Study Feb 25 2015 
ImmuCell to Present at LD Micro Conference on December 2, 2014 Nov 25 2014 
ImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results Nov 03 2014 
ImmuCell Corp. Reports Operating Results (10-Q) Nov 08 2010 
ImmuCell Corp. Reports Operating Results (10-Q) Aug 16 2010 
ImmuCell Corp. Reports Operating Results (10-Q) May 06 2010 
ImmuCell Corp. Reports Operating Results (10-Q) Nov 04 2009 
ImmuCell Corp. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Mid-Morning Market Update: Markets Open Lower; Microsoft Plans To Cut 7,800 Jobs Jul 08 2015
7-8-2015 “ImmuCell Corp. Increases Sales Guidance for Second Quarter of 2015? Jul 08 2015
IMMUCELL CORP /DE/ Files SEC form 8-K, Regulation FD Disclosure Jul 08 2015
UPDATE: ImmuCell Raises Q2 Sales Outlook Jul 08 2015
ImmuCell Corp. Increases Sales Guidance for Second Quarter of 2015 Jul 08 2015
IMMUCELL CORP /DE/ Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 12 2015
IMMUCELL CORP /DE/ Financials May 22 2015
10-Q for ImmuCell Corp. May 14 2015
5-12-2015 “ImmuCell Announces Results for First Quarter of 2015? May 12 2015
IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition May 12 2015
ImmuCell Announces Results for First Quarter of 2015 May 12 2015
Q1 2015 ImmuCell Corp Earnings Release - After Market Close May 12 2015
5-6-2015 “ImmuCell to Announce First Quarter 2015 Financial Results” May 06 2015
ImmuCell to Announce First Quarter 2015 Financial Results May 06 2015
4-15-2015 “ImmuCell Board of Directors Amends Its Common Stock Rights Plan” Apr 15 2015
IMMUCELL CORP /DE/ Files SEC form 8-K, Other Events Apr 15 2015
ImmuCell Board of Directors Amends Its Common Stock Rights Plan Apr 15 2015
4-14-2015 “ImmuCell Announces New Bacteriocin Collaboration With The University of Massachusetts... Apr 14 2015
ImmuCell Announces New Bacteriocin Collaboration With the University of Massachusetts Amherst Apr 14 2015
IMMUCELL CORP /DE/ Files SEC form 10-K, Annual Report Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK